Suppr超能文献

基于 Eudragit RL/RS 的基质片剂用于双氯芬酸持续释放的加工和制剂参数的多响应优化。

Multiple response optimization of processing and formulation parameters of Eudragit RL/RS-based matrix tablets for sustained delivery of diclofenac.

机构信息

a Kayyali Research Chair for Pharmaceutical Industries, Department of Pharmaceutics , King Saud University , Riyadh , Saudi Arabia.

b Department of Industrial Pharmacy, College of Pharmacy , Assiut University , Assiut , Egypt.

出版信息

Pharm Dev Technol. 2017 Nov;22(7):928-938. doi: 10.1080/10837450.2016.1212880. Epub 2016 Jul 28.

Abstract

CONTEXT

Multiple response optimization is an efficient technique to develop sustained release formulation while decreasing the number of experiments based on trial and error approach.

OBJECTIVE

Diclofenac matrix tablets were optimized to achieve a release profile conforming to USP monograph, matching VoltarenSR and withstand formulation variables. The percent of drug released at predetermined multiple time points were the response variables in the design. Statistical models were obtained with relative contour diagrams being overlaid to predict process and formulation parameters expected to produce the target release profile.

MATERIALS AND METHODS

Tablets were prepared by wet granulation using mixture of equivalent quantities of Eudragit RL/RS at overall polymer concentration of 10-30%w/w and compressed at 5-15KN.

RESULTS AND DISCUSSION

Drug release from the optimized formulation E4 (15%w/w, 15KN) was similar to Voltaren, conformed to USP monograph and found to be stable. Substituting lactose with mannitol, reversing the ratio between lactose and microcrystalline cellulose or increasing drug load showed no significant difference in drug release. Using dextromethorphan hydrobromide as a model soluble drug showed burst release due to higher solubility and formation of micro cavities.

CONCLUSION

A numerical optimization technique was employed to develop a stable consistent promising formulation for sustained delivery of diclofenac.

摘要

背景

多响应优化是一种有效的技术,可以在减少基于反复试验的实验数量的同时开发缓释制剂。

目的

优化双氯芬酸钠基质片剂,以实现符合 USP 专论的释放曲线,与 VoltarenSR 相匹配,并耐受制剂变量。在预定的多个时间点释放的药物百分比是设计中的响应变量。获得统计模型,并叠加相对轮廓图,以预测可能产生目标释放曲线的工艺和制剂参数。

材料和方法

使用总量为 10-30%w/w 的 Eudragit RL/RS 混合物通过湿法制粒制备片剂,并在 5-15KN 下压缩。

结果与讨论

优化配方 E4(15%w/w,15KN)的药物释放与 Voltaren 相似,符合 USP 专论,且稳定。用甘露醇替代乳糖,改变乳糖和微晶纤维素的比例,或增加药物负载,对药物释放没有显著影响。使用右美沙芬氢溴酸盐作为模型可溶性药物由于更高的溶解度和微腔的形成而表现出突释。

结论

采用数值优化技术开发了一种稳定一致的有前途的双氯芬酸钠持续释放制剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验